Godavari Drugs Limited reported a net profit of ₹1.11 crore for the quarter ended June 30, 2026, rising 7% from ₹1.10 crore in the same period last year. Revenue from operations expanded by 17% to ₹28.00 crore, compared to ₹23.81 crore in Q1FY25. On a sequential basis, however, profit fell 14% from ₹1.29 crore in the preceding quarter, as revenue contracted to ₹28.00 crore from ₹33.16 crore in Q4FY25.

The Secunderabad-based pharmaceutical firm saw its total expenses rise to ₹26.93 crore in Q1FY26, up from ₹22.52 crore in Q1FY25. This increase was driven primarily by higher costs of materials consumed, which jumped to ₹26.15 crore from ₹17.99 crore year-on-year. Despite the revenue growth, the surge in input costs compressed margins, resulting in a lower absolute profit figure compared to the strong finish in FY25.

Capital Raise and Warrant Conversion

In addition to approving the unaudited financial results, the Board of Directors authorized the allotment of equity shares upon the conversion of warrants. A total of 7,86,690 warrants were converted into an equal number of equity shares at an issue price of ₹89 per share. This transaction involved the receipt of ₹5.25 crore, representing 75% of the issue price per warrant.

The allotment was made on a preferential basis to individuals classified under the "Promoter Category." The post-allotment paid-up equity share capital increased from ₹10.13 crore to ₹10.91 crore. The share capital now consists of 1,09,14,125 equity shares with a face value of ₹10 each.

What the Numbers Show

A notable divergence exists between the company’s revenue growth and its cost structure. While revenue grew 17% year-on-year, the cost of materials consumed surged by 45% over the same period. This suggests significant pressure on gross margins, likely due to higher input costs or a shift in product mix towards lower-margin items. Furthermore, other income contributed ₹15.10 lakh to the bottom line, accounting for approximately 13% of the net profit, highlighting a modest but present reliance on non-operating income streams.

Fund Utilization Update

Godavari Drugs also filed its statement on the deviation or variation in the use of proceeds from its preferential issue dated March 18, 2026. The company raised ₹44.12 crore, primarily for capital expenditure related to manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates, as well as working capital requirements. For the quarter ended June 2026, the company utilized ₹76.33 lakh towards capital expenditure. There was no deviation reported in the use of funds raised.

The results were reviewed by the Audit Committee and approved by the Board at its meeting held on August 14, 2026. The independent auditor, Ayyadevara & Co., issued a review report stating that nothing came to their attention to cause them to believe that the statement does not disclose the information required under SEBI Listing Regulations.

Godavari Drugs has issued a corrigendum to its earlier intimation regarding the scheduling of its Board Meeting, correcting a typographical error in the proposed date. The company clarified that the Board Meeting, originally misstated as taking place on August 24, 2026, will actually be held on Friday, August 14, 2026. This correction ensures that stakeholders and regulatory bodies are aware of the accurate timeline for the approval of the Un-Audited Financial Results for the first quarter ended June 30, 2026.

The corrigendum was submitted on August 11, 2026, to the General Manager – Listing at the Corporate Relations Department of BSE Limited. The communication references the original intimation letter dated August 10, 2026, which was filed pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company attributed the discrepancy to an inadvertent error in the body of the original letter, while noting that the subject line had correctly indicated the August 14 date.

Key Details of the Correction

The following table outlines the specific details of the corrigendum and the associated Board Meeting:

All other contents of the original intimation letter dated August 10, 2026, remain unchanged. The company expressed regret for the inadvertent error and requested that the exchange take the corrigendum on record. The document was signed by Venkatesh Achanta, Company Secretary & Compliance Officer of Godavari Drugs Limited.

What This Means for Shareholders

For investors and analysts tracking Godavari Drugs , this correction confirms that the financial results for Q1FY27 will be discussed and approved earlier than the erroneously stated date. The Board Meeting on August 14, 2026, remains the critical milestone for the release of the quarterly performance metrics, including revenue, net profit, and operational highlights for the period ended June 30, 2026. Stakeholders should monitor official announcements from the company and BSE Limited following this date for the finalized financial data.